Skip to Main Content
Contribute Try STAT+ Today

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of maple bourbon for the occasion. Winter, after all, is nearly upon us. What is upon us right now, however, is our ever-growing to-do list. Sound familiar? So… here are some items of interest. Have a great day, everyone. …

AstraZeneca (AZN) is dropping plans to test its Covid-19 vaccine as a booster in the U.S., Bloomberg News writes, citing a letter sent to participants in the clinical trial that urged volunteers to seek a third dose elsewhere. After discussions with the U.S. government, it became clear that the drug maker was unlikely to pursue plans to assess a third dose of its vaccine, according to the letter sent by New York’s Montefiore Medical Center to trial participants. AstraZeneca was one of the first vaccine developers out of the gate, but has yet to win clearance to sell the shot in the U.S. after facing questions about its clinical trial results and side effects.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment